Telotristat Etiprate for Carcinoid Syndrome Therapy
Public ClinicalTrials.gov record NCT02063659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
Study identification
- NCT ID
- NCT02063659
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- Telotristat etiprate Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2014
- Primary completion
- Mar 28, 2016
- Completion
- Mar 28, 2016
- Last update posted
- Feb 25, 2018
2014 – 2016
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lexicon Investigational Site | Stanford | California | 94305 | — |
| Lexicon Investigational Site | Orlando | Florida | 32806 | — |
| Lexicon Investigational Site | Iowa City | Iowa | 52242 | — |
| Lexicon Investigational Site | Lexington | Kentucky | 40536 | — |
| Lexicon Investigational Site | Boston | Massachusetts | 02215 | — |
| Lexicon Investigational Site | Buffalo | New York | 14263 | — |
| Lexicon Investigational Site | New York | New York | 10029 | — |
| Lexicon Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02063659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2018 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02063659 live on ClinicalTrials.gov.